Protalix BioTherapeutics, Inc. (PLX)
Protalix BioTherapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Protalix BioTherapeutics, Inc. (PLX) is a Biotechnology company based in US with a market capitalization of $190.1M. Revenue declined 1.2% year-over-year and free cash flow was negative at -$13.6M. This page tracks PLX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 213 employees · IPO May 15, 1998
Valuation
Valuation & price
$1.98as of May 17, 2026· -37.1% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
3.94
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$190.1M
Market cap
-1.2%
Revenue growth (YoY)
47.9%
Gross margin
-$13.6M
Free cash flow (USD)
-$22M
Net debt
Net cash position
8.3%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 13, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Protalix BioTherapeutics, Inc.'s market cap?
Protalix BioTherapeutics, Inc. (PLX) has a market capitalization of $190.1M.
What is PLX's P/E ratio?
A meaningful P/E ratio is not available for PLX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is PLX's price-to-book (P/B) ratio?
PLX trades at 3.94 times book value per share.
Are insiders buying PLX stock?
SEC Form 4 filings show no open-market insider buys at Protalix BioTherapeutics, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.